Status:
UNKNOWN
Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Hepatic Encephalopathy
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The study aimed to assess the effectiveness and safety of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
Detailed Description
Hepatic encephalopathy continues to be a major clinical problem in cirrhosis. Patients with minimal hepatic encephalopathy are at risk for accidents, had a decline in work performance, or complain of ...
Eligibility Criteria
Inclusion
- Cirrhosis and diagnosis of minimal hepatic encephalopathy using psychometric tests and critical flicker frequency
Exclusion
- Hepatic encephalopathy grade 1 to 4
- Use of drugs to treatment of hepatic encephalopathy (lactulose, neomycin)
- Psychoactive substance use within 72 hours
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2010
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00896831
Start Date
November 1 2008
End Date
September 1 2010
Last Update
June 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil